Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578801 | 0.82 | KMT2A (0.58) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL579155 | 0.81 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL27813026 | 0.79 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL20094931 | 0.79 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL8513974 | 0.79 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL578908 | 0.79 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL578811 | 0.79 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL578868 | 0.79 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL18709576 | 0.77 | NAPRT (0.59) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A | |
| SCHEMBL18590905 | 0.77 | CYP3A4 (0.48) | SLC1A3SLC1A2SLC1A1NAPRTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841302-B2 | HCV inhibitor and therapeutic agent combinations | PTC THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070412-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | SLC1A3 4340/4885SLC1A2 4578/4885SLC1A1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.